Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Issues Quarterly Earnings Results

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) released its quarterly earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, Zacks reports.

Greenland Mines Ltd. Common Stock Stock Performance

Shares of NASDAQ:GRML traded down $0.00 during midday trading on Monday, reaching $0.20. The company’s stock had a trading volume of 4,741,389 shares, compared to its average volume of 4,195,392. Greenland Mines Ltd. Common Stock has a fifty-two week low of $0.16 and a fifty-two week high of $0.95. The firm has a 50 day moving average price of $0.23 and a two-hundred day moving average price of $0.36. The firm has a market capitalization of $27.52 million, a price-to-earnings ratio of -0.62 and a beta of 7.13.

Insider Activity at Greenland Mines Ltd. Common Stock

In other Greenland Mines Ltd. Common Stock news, Director Jason David Sawyer bought 240,000 shares of the stock in a transaction on Wednesday, July 22nd. The stock was acquired at an average cost of $0.23 per share, for a total transaction of $55,200.00. Following the completion of the acquisition, the director owned 240,000 shares in the company, valued at $55,200. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Riad Hussein El-Dada sold 175,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $0.23, for a total value of $40,250.00. Following the completion of the transaction, the director directly owned 175,000 shares in the company, valued at approximately $40,250. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 11.30% of the company’s stock.

Institutional Trading of Greenland Mines Ltd. Common Stock

Several hedge funds have recently modified their holdings of GRML. XTX Topco Ltd lifted its position in shares of Greenland Mines Ltd. Common Stock by 101.2% during the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock valued at $46,000 after acquiring an additional 80,768 shares during the period. Jane Street Group LLC bought a new stake in Greenland Mines Ltd. Common Stock in the fourth quarter valued at $64,000. Renaissance Technologies LLC bought a new stake in Greenland Mines Ltd. Common Stock in the fourth quarter valued at $126,000. Finally, Geode Capital Management LLC raised its holdings in shares of Greenland Mines Ltd. Common Stock by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after purchasing an additional 167,905 shares during the period. Institutional investors own 20.07% of the company’s stock.

Wall Street Analyst Weigh In

GRML has been the topic of several analyst reports. Weiss Ratings cut shares of Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Wall Street Zen raised Greenland Mines Ltd. Common Stock to a “sell” rating in a research note on Saturday, May 2nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Greenland Mines Ltd. Common Stock Company Profile

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.